Background: The metastatic potential of breast cancer cells has been strongly associated with overexpression of the chemokine CXCL12 and the activity of its receptor CXCR4. Lidocaine, a local anaesthetic that can be used during breast cancer excision, inhibits the growth, invasion, and migration of cancer cells. We therefore investigated, in a breast cancer cell line, whether lidocaine can modulate CXCL12-induced responses. Methods: Intracellular calcium, cytoskeleton remodelling, and cell migration were assessed in vitro in MDA-MB-231 cells,
Editor's key points
Breast cancer metastasis involves chemokine signalling that modulates cytoskeletal structure and motility, which might be sensitive to local anaesthetics. Lidocaine inhibited CXCR4 mediated migration of a human breast cancer cell line in vitro involving changes in intracellular calcium release and the actin cytoskeleton. These findings provide a molecular mechanism for possible beneficial effects of lidocaine in breast cancer surgery through reduced tumour cell migration and metastasis. Clinical studies are necessary to establish a clinical role for lidocaine in reducing metastasis and improving outcomes in cancer surgery.
Breast cancer is the most common diagnosed tumour and represents the second leading cause of death in women. Although chemotherapy, endocrine therapy, and radiotherapy are effective, surgical removal of the tumour is still the best option for a positive outcome. 1 Retrospective and clinical studies on patient cohorts undergoing cancer surgery suggest that perioperative use of regional anaesthesia and local anaesthetic agents might improve outcome. 2 Recent investigations have shown that in lung carcinoma, local anaesthetics have anti-metastatic potential through inhibition of cancer cell migration and of Src signalling. 3 The metastatic potential of breast cancer has been strongly associated with overexpression of the chemokine CXCL12 and the activity of its receptor CXCR4. 4e7 Under homeostatic conditions, the CXCL12/CXCR4 axis plays key roles in development and immunity, while in cancer, it promotes tumour survival, invasion, and metastasis. 8, 9 Chemokines have emerged as key controllers of integrin function and cell locomotion. 9 Chemokine receptors are differentially expressed by all leukocytes and many non-haematopoietic cells, including cancer cells, and constitute the largest branch of the g subfamily of rhodopsinlike G protein-coupled receptors (GPCR), a receptor superfamily that represents the most successful target of small molecule inhibitors in modern pharmacology. 10, 11 As local anaesthetics are known to modulate the activity of specific G-proteins, 12, 13 we investigated whether lidocaine at clinical concentrations can modulate CXCR4 responses induced by CXCL12. , and glutaMAX (619650-026, GIBCO, ThermoFisher Scientific, Switzerland) supplemented with fetal bovine serum 10% (16000-044, GIBCO, ThermoFisher), and penicillin-streptomycin 1% (15070063, GIBCO, ThermoFisher Scientific). Cells were incubated under standard culture conditions (CO 2 5%, O 2 95%, 37 C), and experiments were performed with cells at 70%e100% confluence.
Methods

Cell line
Reagents
CXCL12 was chemically synthesised as described, 14 and lidocaine was from Sintetica ® (Rapidocain 10 mg ml À1 , Mendrisio, Switzerland). 
Cell viability
Scratch wound assay
Migration of MDA-MB-231 cells stimulated by CXCL12 100 nM was assessed in the presence or absence of lidocaine 10 mM or 100 mM. Cells were grown in six-well plates until confluence for 24 h. A scratch was created in each well using a small pipette tip. 15 For the experiments with the CD44 blocking antibody (MA4400, Invitrogen, Waltham, MA, USA) used at 10 mg ml À1 , cells were grown in 24-well plates until confluence. Stimulation and scratch were performed as described above. Images were recorded with a BD pathway 855 imager for 24 h maintaining cells as described above, at 10Â magnification. The scratch wound area, expressed as percentage of the area at time 0, was quantified using the open-source image analysis software Fiji 16 and normalised to time 0 for each condition.
Chemotaxis assays
Real-time cell migration of MDA-MB-231 cells was measured using the m-Slide chemotaxis system from Ibidi (80326, Martinsried, Germany), according to the manufacturer's instructions. Briefly, MDA-MB-231 cells were seeded at 4Â10 6 cells ml À1 in chemotaxis medium [DMEM, fetal bovine serum 1%, 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (Hepes) 20 mM, pH 7.4] in the central channel of the chemotaxis slide, and were cultured in standard conditions for 8 h to allow adherence. Chemoattractant gradients were generated by applying the following stimuli in the reservoirs of the chemotaxis slide: chemotaxis medium, CXCL12 100 nM, or CXCL12 100 nM with lidocaine 100 mM. Phase contrast images were recorded for 18 h with a time lapse of 15 min using the ImageXpress Micro 4 Imager (Molecular Devices, San Jose, CA, USA) equipped with an incubation system set to CO 2 5%, O 2 95%, 37 C, and with a 4Â objective. Single cell tracking was performed selecting the centre of mass in each frame using the manual tracking plug-in tool for the software ImageJ. Spider plots representing the trajectories of tracked cells, forward migration indexes, accumulated distance, and cell velocity were obtained using the chemotaxis and migration plug-in tool from Ibidi.
Actin polymerisation
Cells grown on poly-D-lysine-coated dishes (P35GC-0-14C, MatTek Corporation, Ashland, MA, USA) were pre-treated with lidocaine 10 mM or 100 mM for 24 h under culture conditions. After washing with phosphate buffered saline, cells were stimulated with complete medium in the presence or absence of CXCL12 100 nM for 15 s, fixed in paraformaldehyde 4% in phosphate buffered saline for 12 min on ice, and permeabilised with Triton-X-100 0.01% for 2 min on ice. Filamentous actin was stained using phalloidin-FITC (4 mg ml
À1
, P-5282, Sigma Aldrich, Saint Louis, MO, USA) for 30 min at room temperature. Samples were analysed by confocal microscopy (Leica SP5, Heerbrugg, Switzerland) at 63Â magnification. Mean fluorescence intensity was quantified using the opensource image analysis software Fiji. 
Statistical analysis
Data are presented as mean (standard deviation). Normal distribution was assessed using Shapiro-Wilk testing. Normally distributed data were analysed with Student's t-test (statistical significance between two groups), or two-way analysis of variance followed by Dunnett's multiple comparisons adjustment (statistical significance between more than two groups).
Results
We first evaluated lidocaine toxicity on MDA-MB-231 cells. Cells were incubated with different concentrations of lidocaine (1 nM, 1, 10, 100 mM) and induction of apoptosis or necrosis was assessed after 24 h. Lidocaine did not induce apoptosis or necrosis at any of the concentrations tested (Fig. 1) .
Lidocaine effects on tumour cell migration
We then investigated whether lidocaine alters MDA-MB-231 chemokinesis or chemotaxis induced by CXCL12, the chemokine agonist of the CXCR4 receptor. For this we used an in vitro scratch wound assay, a technique widely applied for testing in vitro cell migration of epithelial cancer cells, 15 and an in vitro chemotaxis assay that allows tracking directional cell migration in response to a chemotactic gradient. CXCL12 induced significant MDA-MB-231 migration both in the scratch wound assay (9 h, P¼0.0372; 12 h, P¼0.0003; 15, 18, 21 h, P<0.0001) and chemotaxis assay (P¼0.0047), supporting the relevance of the CXCL12/CXCR4 axis in tumour cell migration (Fig. 2) . As shown in Fig. 2A , lidocaine prevented closure of the scratch area induced by CXCL12 at 10 mM or 100 mM (P<0.0001). Moreover, lidocaine abrogated CXCL12 mediated chemotaxis as demonstrated by a significant reduction in the forward migration index (P¼0.0446), without altering cell velocity and cell accumulated distance ( Fig. 2B and C) . These effects were not as a result of changes in CXCR4 surface expression or alterations in receptor trafficking as assessed by flow cytometry (data not shown). Different adhesion molecules expressed on epithelial cells can play a role in cancer cell invasion and metastasis. Therefore, the effect of lidocaine treatment was assessed on the expression of CD44 and CD54 [intercellular adhesion molecule 1 (ICAM-1)] after stimulation with CXCL12. In comparison to untreated cells, lidocaine pre-treatment induced an upregulation of CD44 (P¼0.0226), which was observed also after stimulation with CXCL12 (Fig. 3A, P¼0 .0010), whereas no significant differences were detected in CD54 expression (data not shown). To understand whether lidocaine-mediated CD44 overexpression is essential for inhibition of MDA-MB-231 migration, the effect of CD44 blockade was tested in the scratch wound assay. The CD44-neutralising antibody did not restore cell migration in CXCL12 stimulated cells in the presence of lidocaine (Fig. 3B) , indicating that modulation of this adhesion molecule is not essential for the observed effect, and suggesting that lidocaine directly alters the response to CXCL12.
Lidocaine effects on cytoskeleton remodelling
Remodelling of the cytoskeleton, supported by actin polymerisation, is a crucial process for correct polarisation of cells and motility during cell migration.
17 CXCR4 triggering by CXCL12 induces Ca 2þ mobilisation from intracellular stores as a result of the activation of the Gai pathway. 18 This is an essential pathway for modulation of proteins with Ca 2þ -dependent activity that are involved in remodelling of the cytoskeleton. CXCL12 triggering of CXCR4 resulted in an intracellular Ca 2þ increase, which could be blocked by the Gai inhibitor pertussis toxin. Lidocaine pre-treatment partially inhibited the Ca 2þ mobilisation induced by CXCL12 (Fig. 4A) .
We hypothesised that lidocaine inhibition of intracellular Ca 2þ increase impairs actin polymerisation, explaining the observed reduction in cell migration. Therefore, a specific staining for filamentous actin was performed in MDA-MB-231 cells pre-treated with lidocaine, and stimulated with CXCL12. Exposure of untreated MDA-MB-231 cells to the chemokine resulted in rapid rearrangement of the cortical actin fibres, with pronounced actin polymerisation (Fig. 4B) . Lidocaine pretreatment at 10 and 100 mM inhibited cytoskeleton rearrangement after CXCL12 stimulation (Fig. 4B) , supporting the results obtained in the migration assay. Quantification of mean fluorescence intensity of phalloidin, which indicates levels of actin polymerisation, confirmed the above data, showing a significant decrease when cells pre-treated with lidocaine at 10 or 100 mM were stimulated with CXCL12 (Fig. 4C, P¼0 .0011, P¼0.0020, respectively). Of note, high lidocaine concentrations (100 mM) also decreased basal actin polymerisation compared with untreated cells (Fig. 4C, P¼0 .0202).
Discussion
We show that lidocaine, at clinical concentrations, inhibits CXCL12-induced CXCR4 signalling, which impairs the essential cascade of cytoskeleton remodelling, leading to a reduced migration of breast cancer cells. Epidemiological studies have suggested an association between regional anaesthesia and a reduction in the incidence of cancer recurrence. 2 The underlying mechanism is still unknown. One report suggested a possible systemic effect of reabsorbed local anaesthetic in preventing invasiveness of tumour cells released from the primary tumour during surgery. 19 This hypothesis has been supported by in vitro studies, demonstrating that lidocaine affects motility of a lung cancer cell line by reducing ICAM-1 and Src phosphorylation after tumour necrosis factor stimulation. The reduced activity of ICAM-1 on tumour cells could inhibit their adhesion to vascular endothelium, thus preventing migration into tissues. 3 And in a murine model of breast cancer metastasis, lidocaine reduced pulmonary metastasis, perhaps by anti-inflammatory or anti-angiogenic mechanisms. 20 Recent studies have shown that, in septic patients, lidocaine can block neutrophil migration by inhibiting cell arrest and transmigration through endothelial cells, affecting G-protein signalling, without modulating expression of adhesion molecules. 21 The present study, focusing on breast tumour cells, shows that lidocaine, at clinical concentrations, can inhibit chemokine-induced cancer cell migration by directly inhibiting the activity of CXCR4. These results agree with studies performed on different cell types, 3,21e23 showing that lidocaine affects the activity of the chemokine class of GPCR, and providing new insights into the molecular mechanisms governing its inhibitory effect on cell migration. Increasing evidence indicates that different classes of anaesthetics can exert either pro-or anti-metastatic effects, which depend on cancer cell type, dosage, and administration protocol. 24 As an example, a potential pro-metastatic role of volatile anaesthetics involving CXCR2 expression has been described in ovarian cancer cells. 25 Our data support further studies to validate the role of lidocaine as an anti-metastatic agent, and for reconsidering the perioperative treatment in breast cancer. Indeed, perioperative continuous i.v. infusion of lidocaine has been safely used to reduce systemic inflammation and bowel dysfunction after abdominal surgery. 26 The chemokine system represents a fundamental communication bridge between cancer and stromal cells, essential in maintaining and supporting tumour growth and metastasis. The chemokine receptor CXCR4 and its ligand CXCL12, are widely expressed in several types of tumours, and are both targeted in cancer therapy. 27 Numerous reports highlight the crucial involvement of the CXCL12/CXCR4 chemokine axis specifically in breast cancer cell metastasis to bone, lung, and brain. 4, 28 In our work, lidocaine at clinical concentrations was able to block CXCR4-mediated cell migration, acting on the downstream signalling cascade. Lidocaine, by inhibiting CXCL12-dependent Ca 2þ release and actin polymerisation, impaired the cytoskeleton remodelling required for directional cell migration. Of note, high doses of lidocaine induced the loss of cortical actin stress fibres, suggesting alteration of the basal cellular cytoskeleton architecture. Adhesion molecules, expressed on tumours, mediate the interaction between cancer cells and the microenvironment, sustaining tumour progression and metastasis. 29 We found that in MDA-MB-231 cells, lidocaine treatment promotes upregulation of CD44 expression, a transmembrane glycoprotein important for cancer interaction with hyaluronic acid, an essential component of the extracellular matrix. Fuchs and colleagues 30 pointed out a regulatory interplay between CD44 and the CXCL12/CXCR4 axis, describing a direct role of CD44 in the signalling of this chemokine pathway. Our results show that the blockade of CD44 does not restore CXCL12-mediated cell migration in MDA-MB-231 breast cancer cells, demonstrating that the lidocaine effect is CD44-independent.
In conclusion, lidocaine can block a pathway involved in cancer progression and metastasis, which opens the way for further investigations of the activity of lidocaine on cells of the immune system that might contribute to improved cancer outcomes. Studies performed ex vivo on tumour and infiltrating cells isolated after surgical removal from patients treated with lidocaine and clinical trials are needed to confirm these in vitro findings to establish a role for local anaesthetics in cancer therapy. 
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